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Identification of vulnerability to severe coronavirus disease 2019 (COVID-19) is extremely 
important and might allow optimised shielding and easing of lockdown. The disease is 
attributed to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which 
enters host cells through binding to angiotensin converting enzyme 2 (ACE2) on the cell 
surface. Clinical syndromes such as hypertension that display reduced ACE2 expression tend 
to correlate with a more severe disease course, whereas treatments which upregulate ACE2 
such as the use of angiotensin converting enzyme inhibitors (ACE-i) appear to have a 
protective effect against COVID-19. Pre-clinical studies have shown that plasma soluble 
ACE2 could render SARS-CoV-2 inactive in a dose-dependent manner. The association of 
clinical syndromes or treatments that impact ACE2 expression and clinical severity of 
COVID-19 infection combined with the reduction in viral load with human recombinant 
serum ACE2 shown in pre-clinical studies indicate a key role for ACE2 in determining 
COVID-19 severity. In conclusion, we propose that measurement of ACE2 level may help 
identify individuals at risk of severe infection where targeted shielding can be used and could 
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Identification of vulnerability to severe COVID-19 is extremely important, and might allow 
optimised shielding and easing of lockdown. We propose a pathological role for soluble 
angiotensin converting enzyme (sACE2) modulating COVID-19 disease severity, which 
could be used in screening and treatment. 
Hypertension, diabetes and obesity are risk factors for severe disease.1 SARS-CoV-2 
enters the host cell through the spike (S) protein binding to ACE2,2 and since ACE-inhibitors 
(ACE-i) and angiotensin-II receptor blockers (ARB) upregulate cellular ACE2 expression, 
this could theoretically facilitate SARS-CoV-2 binding and severe disease manifestation, 
while renin-angiotensin-aldosterone inhibition appears protective.3 
After SARS-CoV-2 binds to host cells, ACE2 expression and enzymatic activity are 
significantly reduced through enhanced shedding, with the extracellular component of ACE2 
cleaved and resultant soluble protein released. The resultant increased sACE2 may act as a 
‘dummy’ receptor, binding the S protein on circulating virus. Thus, higher numbers of ACE2 
receptors expressed prior to first binding event may lead to higher sACE2 level and reduced 
circulating SARS-CoV-2 with ‘active’ S protein sites, reduced numbers of affected host cells, 
and less systemic impact. Therefore, conditions that upregulate ACE2 may confer protection, 
whereas reduced ACE2 expression may result in more severe disease.  
Clinical findings support such pathological role for reduced ACE2 levels in mediating 
disease severity. Patients with hypertension, exhibiting marked ACE up-regulation and ACE2 
downregulation, are at higher risk of severe disease, whereas those taking ACE-i/ARB 
exhibit less disease severity and lower mortality.3 The ACE2 gene is linked to metabolic 
syndrome and obesity.4 ACE2 gene knockout leads to metabolic syndrome in mice. In 
patients with diabetic renal disease, ACE2 expression is reduced compared to patients with 
non-diabetic renal disease or controls. Lower ACE2 expression in obese patients and 
metabolic syndrome may explain worse outcomes with COVID-19.1 
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The ACE2 gene is located on the X-chromosome, and ACE2 activity and expression in 
rats was decreased by oophorectomy and restored by oestrogen. Thus, women would be 
expected to have higher ACE2 activity, which might explain better outcomes. Recent studies 
show that human recombinant sACE2 (hrsACE2) can bind and neutralise SARS-CoV-2 S 
protein,5 reducing SARS-CoV-2 entry into cells in a dose-dependent manner.2   
The association of clinical syndromes and treatments that impact ACE2 expression and 
the reduction in viral load with hrsACE2, indicate a key role for ACE2 in COVID-19 
severity. We propose that measurement of ACE2 level may help identify individuals at risk 
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